Retail-Drug Stores and Proprietary Stores · SIC 5912

AiXin Life International, Inc.

AIXN

Watch

Latest revenue

$302.0K

as of 2025-09-30

Latest net income

$-340.5K

as of 2025-09-30

Net margin

-112.7%

as of 2025-09-30

Price · 5Y

-55.1% / yr 68.9 pts / yr vs S&P 500 98.2% total
Compare:

Live market

delayed ≤15 min
$0.26
0.00%
Market cap
$6.5M
Enterprise value
$6.5M
P/E (trailing)
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$0.68
52-wk low
$0.10
Beta
Shares out
25.0M

5-year trend

What this company does

AI

Item 1 Business. Overview As used in this report, unless the context requires otherwise, all references to “AiXin Colorado” refer to AiXin Life International, Inc., a Colorado holding company, and references to “Aixin Life,” we,” “us,” “our,” the “Registrant,” the “Company” or “our Company” are to AiXin Colorado and its subsidiaries*. We are a Colorado holding company and conduct substantially all of our operations through our operating companies established in the People’s Republic of China, or the PRC. Our focus is on providing health and wellness products to the growing middle class in China. We currently develop, manufacture, market and sell premium-quality healthcare, nutritional…

AI summary unavailable — showing raw filing excerpt

Generated from AIXN's filing dated 2026-05-15

Key risks

AI

Item 1A. Risk Factors An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with all of the other information included in this report, before making an investment decision. If any of the following risks actually occurs, our business, financial condition or results of operations could suffer. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment. Risks Associated with Our Company We incurred net losses in 2025 and 2024 and may not be able to continue to operate as a going concern. We incurred a net loss of $2,042,463 and $2,768,341 for the years ended…

AI summary unavailable — showing raw filing excerpt

Generated from AIXN's filing dated 2026-05-15

Profitability

Operating margin

-169.2%

150.1%

Net margin

-137.1%

89.4%

Return on equity

31.1%

51.9%

Return on assets

-63.8%

1.6%

Leverage

Debt / equity

-1.49×

26.7%

Debt / assets

305.2%

54.8%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q4 2025

2025-12-31

$327.7K-53.4%$-628.8K+56.4%-191.9%

Q3 2025

2025-09-30

$302.0K-67.8%$-340.5K+37.7%-112.7%

Q2 2025

2025-06-30

$460.9K-65.4%$-351.5K-98.8%-76.3%

Q1 2025

2025-03-31

$398.8K-53.2%$-721.7K-19.6%-181.0%

Q4 2024

2024-12-31

$703.7K$-1.4M-204.9%

Q3 2024

2024-09-30

$936.4K-12.2%$-546.2K-24.7%-58.3%

Q2 2024

2024-06-30

$1.3M-9.7%$-176.8K-81.2%-13.3%

Q1 2024

2024-03-31

$851.6K$-603.6K-70.9%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Retail-Drug Stores and Proprietary Stores · SIC 5912

Your notes

Keep private notes on AIXN — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

No insider transactions on file for AIXN in the last 12 months.

Source: SEC Form 4 filings. Backfill runs nightly.

Who owns AIXN

No institutional holdings on file for AIXN yet.

Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).

Top questions investors are asking

Coming once AIXN's latest filing finishes processing.